Discounted Cash Flow Rating

Neutral

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Sell

Price to Earnings Rating

Strong Sell

Analyst Rating

Sell

Upgrade To View Simple Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Exponential Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Relative Strength Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Standard Deviation Rating

Upgrade

Upgrade To Get Access

Upgrade To View Williams %R Rating

Upgrade

Upgrade To Get Access

Upgrade To View Average Directional Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Insider Trading Rating

Upgrade

Upgrade To Get Access

Wall Street Data Solutions Rating

Buy

A

Vigil Neuroscience, Inc. Common Stock (VIGL)

Biological Products, (no Disgnostic Substances)

https://www.vigilneuro.com

Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families.

100 FORGE ROAD, SUITE 700
WATERTOWN, MA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

01/07/2022

Market Cap

126,079,155

Shares Outstanding

35,880,000

Weighted SO

35,877,421

Total Employees

N/A

Upcoming Earnings

08/13/2024

Similar Tickers

MOLN --.--%

PMVP --.--%

GLUE --.--%

TRDA --.--%

THRD --.--%

CGEM --.--%

EWTX --.--%

RLYB --.--%

PEPG --.--%

Beta

2.0110

Last Div

0.0000

Range

2.47-9.24

Chg

-0.2800

Avg Vol

574270

Mkt Cap

126079155

Exch

NASDAQ

Country

US

Phone

857 254 4445

DCF Diff

2.4747

DCF

0.9853

Div Yield

0.0000

P/S

65.1909

EV Multiple

-1.1386

P/FV

1.5128

Div Yield %

0.0000

P/E

-1.5387

PEG

-3.2927

Payout

0.0000

Current Ratio

8.3883

Quick Ratio

8.3883

Cash Ratio

3.4693

DSO

100.0259

DIO

0.0000

Op Cycle

100.0259

DPO

1152.7171

CCC

-1052.6913

Gross Margin

0.7678

Op Margin

-46.5724

Pretax Margin

-43.3485

Net Margin

-43.3485

Eff Tax Rate

-0.0341

ROA

-0.7729

ROE

-0.7602

ROCE

-0.9218

NI/EBT

1.0000

EBT/EBIT

0.9308

EBIT/Rev

-46.5724

Debt Ratio

0.1236

D/E

0.1572

LT Debt/Cap

0.1273

Total Debt/Cap

0.1359

Int Coverage

-86.1923

CF/Debt

-5.2370

Equity Multi

1.2720

Rec Turnover

3.6491

Pay Turnover

0.3166

Inv Turnover

0.0000

FA Turnover

0.1136

Asset Turnover

0.0178

OCF/Share

-1.7307

FCF/Share

-1.7323

Cash/Share

2.1367

OCF/Sales

-36.3014

FCF/OCF

1.0009

CF Coverage

-5.2370

ST Coverage

-72.4530

CapEx Coverage

-1080.1077

Div&CapEx Cov

-1080.1077

P/BV

1.5128

P/B

1.5128

P/S

65.1909

P/E

-1.5387

P/FCF

-1.7942

P/OCF

-1.8374

P/CF

-1.8374

PEG

-3.2927

P/S

65.1909

EV Multiple

-1.1386

P/FV

1.5128

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Jul 03, 22:43 SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CHTR, TASK, VIGL, STRM on Behalf of Shareholders GlobeNewswire Inc. Jun 02, 23:14 $HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger – PRA, AXL, SWTX and VIGL Benzinga Jun 01, 23:42 $HAREHOLDER NOTICE: The M&A Class Action Firm Continues To Investigate The Merger - PRA, AXL, SWTX and VIGL GlobeNewswire Inc. May 24, 14:39 SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SGMA, VIGL, STRR on Behalf of Shareholders Benzinga May 21, 23:30 Vigil Neuroscience Enters into Definitive Merger Agreement to be Acquired by Sanofi GlobeNewswire Inc. May 21, 23:30 Vigil Neuroscience Enters into Definitive Merger Agreement to be Acquired by Sanofi GlobeNewswire Inc. May 21, 23:15 Communiqué de presse : Sanofi va acquérir Vigil Neuroscience, Inc. et ajouter un nouveau médicament expérimental pour le traitement de la maladie d’Alzheimer à son portefeuille en neurologie GlobeNewswire Inc. May 21, 23:15 Press Release: Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline GlobeNewswire Inc. Jun 27, 06:00 Vigil Neuroscience Announces $40 Million Strategic Investment from Sanofi MarketWatch Jan 06, 05:58 The Russell 2000 Index has soared, but you might be better off looking elsewhere for quality small-cap stocks GlobeNewswire Inc. Jan 03, 16:30 Vigil Neuroscience Provides 2023 Year-in-Review and Highlights Upcoming 2024 Milestones MarketWatch Jan 02, 12:26 The Russell 2000 Index has soared, but you might be better off looking elsewhere for quality small-cap stocks MarketWatch Jan 02, 12:26 The Russell 2000 Index has soared, but you might be better off looking elsewhere for quality small-cap stocks GlobeNewswire Inc. Nov 22, 16:05 Vigil Neuroscience to Present at Evercore ISI 6th Annual HealthCONx Conference Benzinga Nov 17, 13:01 Why Dolby Laboratories Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Friday's Mid-Day Session

Revenue Product Segmentation